Gyre Pharmaceuticals has completed participant enrolment for its 52-week Phase III clinical trial assessing Pirfenidone ...

Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives ...

Partnership further supports trial recruitment; FORTITUDE-HCM to be highlighted at upcoming HCMA Annual Patient MeetingEnrollment underway for ...

EV25 was generally well-tolerated and demonstrated a good safety profile, with no observable dose-dependent safety trends.

Clarametyx has concluded subject enrolment in its Phase Ib/IIa study of CMTX-101, an immune-enhancing antibody therapy being ...

A Dutch study involving more than 1100 men found that the antioxidant supplement Impryl did not improve fertility. The trial, ...

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and ...

This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced non–small-cell lung cancer (NSCLC). Although all authors ...

Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...